4-(4’-氯苄氧基)苯基硼酸 | 870778-91-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(4’-氯苄氧基)苯基硼酸
• 中文别名: 4-(4-氯苄氧基)苯硼酸；4-(4'-氯苄氧基)苯基硼酸
• 英文名称: 4-(4'-chlorobenzyloxy)phenylboronic acid
• 英文别名: [4-[(4-chlorophenyl)methoxy]phenyl]boronic acid
• CAS: 870778-91-9
• 化学式: C₁₃H₁₂BClO₃
• mdl: MFCD07784349
• 分子量: 262.5
• InChiKey: RONZDKNBNIRWIV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.68
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2931900090
• 危险性描述：
  H413
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501

反应信息

• 作为反应物：
  描述：

  4-(4’-氯苄氧基)苯基硼酸 、 tert-butyl 2-(4-bromo-N-isopropoxyphenylsulfonamido)acetate 在 potassium phosphate 、 四(三苯基膦)钯 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.33h， 以25%的产率得到tert-butyl 2-(4'-(4-chlorobenzyloxy)-N-isopropoxybiphenyl-4-ylsulfonamido)acetate
  参考文献：
  名称：

  N-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for Osteoarthritis

  摘要：

  Matrix metalloproteinase-13 (MMP-13) is a key enzyme implicated in the degradation of the extracellular matrix in osteoarthritis (OA). For this reason, MMP-13 synthetic inhibitors arc being sought as potential therapeutic agents to prevent cartilage degradation and to halt the progression of OA. Herein, we report the synthesis and in vitro evaluation of a new series of selective MMP-13 inhibitors possessing an arylsulfonamidic scaffold. Among these potential inhibitors, a very promising compound was discovered exhibiting nanomolar activity for MMP-13 and was highly selective for this enzyme compared to MMP-1, -14, and TACE. This compound acted as a slow-binding inhibitor of MMP-13 and was demonstrated to be effective in an in vitro Collagen assay and in a model of cartilage degradation. Furthermore, a docking study was conducted for this compound in order to investigate its binding interactions with MMP-13 and the reasons for its selectivity toward MMP-13 versus other MMPs.

  DOI：

  10.1021/jm900261f

文献信息

• [EN] FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS À TITRE DE MODULATEURS DE S1P
  申请人：ABBVIE INC

  公开号：WO2017036978A1

  公开（公告）日：2017-03-09

  The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

  这项发明涉及杂环化合物作为S1P调节剂，包括这种化合物的药物组合物，以及在治疗、缓解或预防由S1P受体介导的疾病或紊乱中的用途。
• PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
  申请人：Bristol-Myers Squibb Company

  公开号：US20150232463A1

  公开（公告）日：2015-08-20

  The disclosure generally relates to compounds of formula I, II, III and IV, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

  该披露通常涉及公式I、II、III和IV的化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。该披露提供了HIV的新型抑制剂，包含这些化合物的药物组合物，以及在治疗HIV感染中使用这些化合物的方法。
• [EN] SPIRO-COMPOUNDS AS S1P MODULATORS<br/>[FR] COMPOSÉS SPIRO EN TANT QUE MODULATEURS DE S1P
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2018083171A1

  公开（公告）日：2018-05-11

  The invention relates to heterocyclic compounds of formula (I) as SIP modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment or alleviation of diseases or disorders mediated by an SIP receptor.

  本发明涉及式(I)的杂环化合物作为SIP调节剂，包含该化合物的药物组合物，以及它们在治疗或缓解由SIP受体介导的疾病或失调症中的用途。
• Virtual Fragment Screening Identification of a Quinoline-5,8-dicarboxylic Acid Derivative as a Selective JMJD3 Inhibitor
  作者：Assunta Giordano、Federica del Gaudio、Catrine Johansson、Raffaele Riccio、Udo Oppermann、Simone Di Micco

  DOI：10.1002/cmdc.201800198

  日期：2018.6.20

  The quinoline‐5,8 dicarboxylic acid scaffold has been identified by a fragment‐based approach as new potential lead compound for the development of JMJD3 inhibitors. Among them, 3‐(2,4‐dimethoxypyrimidin‐5‐yl)quinoline‐5,8‐dicarboxylic acid (compound 3) shows low micromolar inhibitory activity against Jumonji domain‐containing protein 3 (JMJD3). The experimental evaluation of inhibitory activity against

  喹啉5,8二羧酸支架已被基于片段的方法鉴定为开发JMJD3抑制剂的新的潜在先导化合物。其中，3-（2,4-二甲氧基嘧啶-5-基）喹啉-5,8-二羧酸（化合物3）对含有Jumonji域的蛋白3（JMJD3）的微摩尔抑制活性较低。对JMJD3的七个相关同工型的抑制活性的实验评估突显了对目标生物学靶标的前所未有的选择性。
• Polysubstituted Pyrimidines as mPGES‐1 Inhibitors: Discovery of Potent Inhibitors of PGE ₂ Production with Strong Anti‐inflammatory Effects in Carrageenan‐Induced Rat Paw Edema
  作者：Filip Kalčic、Viktor Kolman、Haresh Ajani、Zdeněk Zídek、Zlatko Janeba

  DOI：10.1002/cmdc.202000258

  日期：2020.8.5

  These compounds are sub‐micromolar inhibitors of PGE2 production (IC50 as low as 12 nM). In order to identify the molecular target of anti‐inflammatory pyrimidines, we performed extensive studies including enzymatic assays, homology modeling and docking. The difluorinated analogue simultaneously inhibits two key enzymes of the arachidonic acid cascade, namely mPGES‐1 and COX‐2, with mPGES‐1 inhibition

  我们报道了对多取代嘧啶进行的广泛的构效关系优化，从而发现了5-丁基-4-（4-苄氧基苯基）-6-苯基嘧啶-2-胺及其二氟类似物。这些化合物是PGE 2产生的亚微摩尔抑制剂（IC 50低至12 nM）。为了确定抗炎嘧啶的分子靶标，我们进行了广泛的研究，包括酶法测定，同源性建模和对接。二氟类似物同时抑制花生四烯酸级联的两个关键酶，即mPGES-1和COX-2，其中mPGES-1的抑制是主要的作用机理。研究的其他嘧啶类是有效的mPGES-1抑制剂，没有观察到对COX-1 / 2酶的抑​​制作用。此外，在急性炎症模型中，两种最有效的化合物在体内被证明是有效的，将角叉菜胶诱导的大鼠爪水肿抑制了36％和46％。这项研究的有希望的结果值得对所选的抗炎候选药物进行进一步的临床前评估。